Volume 66, Issue 1, Pages (July 2004)

Slides:



Advertisements
Similar presentations
1 2 By Hussam A.S. Murad and Khaled A. Mahmoud Department of Pharmacology and Therapeutics Faculty of Medicine, Ain Shams University.
Advertisements

Uric Acid and Hypertension
©2007 RUSH University Medical Center Hyperuricemia in adolescents with primary hypertension: how and when to intervene? Farahnak Assadi, M.D. Professor.
Date of download: 6/21/2016 From: Pathogenesis of Hypertension Ann Intern Med. 2003;139(9): doi: / A pathway.
Seema Jain1, Rebecca Andridge2, Jessica Hellings3
A.M. Thompson, T.G. Pickering  Kidney International 
Thomas G. Pickering, MD, DPhil, William B. White, MD 
Volume 64, Issue 4, Pages (October 2003)
Volume 66, Issue 2, Pages (August 2004)
Gestational Diabetes Lab 4.
Plasma sodium and hypertension
Synthetic smooth muscle cell phenotype is associated with increased nicotinamide adenine dinucleotide phosphate oxidase activity: Effect on collagen secretion 
Volume 69, Issue 9, Pages (May 2006)
Volume 63, Issue 1, Pages (January 2003)
Rapamycin is an effective inhibitor of human renal cancer metastasis1
Hyperuricemia induces endothelial dysfunction
Modulation of articular chondrocyte proliferation and anionic glycoconjugate synthesis by glucosamine (GlcN), N-acetyl GlcN (GlcNAc) GlcN sulfate salt.
Fructokinase activity mediates dehydration-induced renal injury
Hypertension in end-stage renal disease
Preeclampsia: A renal perspective
Volume 63, Issue 3, Pages (March 2003)
Volume 68, Issue 4, Pages (October 2005)
Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats  Julie Chao, Jenny J. Zhang, Kuei-Fu Lin,
Volume 60, Issue 4, Pages (October 2001)
Karen A. Griffin, Maria M. Picken, George L. Bakris, Anil K. Bidani 
Robert Earl Routh, John Hardwick Johnson, Kevin John McCarthy 
Volume 59, Issue 6, Pages (June 2001)
Volume 59, Issue 5, Pages (May 2001)
Volume 57, Issue 3, Pages (March 2000)
Volume 62, Issue 3, Pages (September 2002)
Albumin up-regulates the type II transforming growth factor-beta receptor in cultured proximal tubular cells1  Gunter Wolf, Regine Schroeder, Fuad N.
Angiotensin converting enzyme inhibitor but not angiotensin receptor blockade or statin ameliorates murine adriamycin nephropathy  S.C.W. Tang, J.C.K.
Volume 67, Issue 1, Pages (January 2005)
P.-A. Hueber, P. Waters, P. Clarke, M. Eccles, P. Goodyer 
Volume 64, Issue 4, Pages (October 2003)
Volume 68, Issue 4, Pages (October 2005)
PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice
Volume 68, Issue 2, Pages (August 2005)
Steven J. Rosansky, Richard J. Glassock  Kidney International 
Lori L. Woods, Douglas A. Weeks, Ruth Rasch  Kidney International 
Volume 67, Issue 1, Pages (January 2005)
Volume 87, Issue 2, Pages (February 2015)
Volume 62, Issue 1, Pages (July 2002)
Volume 65, Issue 2, Pages (February 2004)
Volume 66, Issue 2, Pages (August 2004)
Volume 64, Issue 1, Pages (July 2003)
Volume 61, Issue 5, Pages (May 2002)
Volume 56, Pages S31-S37 (December 1999)
Volume 72, Issue 2, Pages (July 2007)
Time to abandon microalbuminuria?
Volume 59, Issue 5, Pages (May 2001)
Volume 60, Issue 6, Pages (December 2001)
Michael W. Steffes, Derek Schmidt, Rebecca Mccrery, John M. Basgen 
Angiotensin II stimulates Pax-2 in rat kidney proximal tubular cells: Impact on proliferation and apoptosis  Shao-Ling Zhang, Jun Guo, Babak Moini, Julie.
Differential Responses of S100A2 to Oxidative Stress and Increased Intracellular Calcium in Normal, Immortalized, and Malignant Human Keratinocytes  Tong.
Volume 81, Issue 8, Pages (April 2012)
Circadian regulation of renal function
Lu-Cheng Cao, Thomas Honeyman, Julie Jonassen, Cheryl Scheid 
Volume 64, Issue 1, Pages (July 2003)
Volume 53, Issue 6, Pages (June 1998)
Volume 75, Issue 12, Pages (June 2009)
Volume 72, Issue 6, Pages (September 2007)
Volume 62, Issue 6, Pages (December 2002)
Larry D. Alexander, Suganthi Alagarsamy, Janice G. Douglas 
Richard A. Zager, Ali Johnson, Sherry Hanson, Vivian Dela Rosa 
CDNA Microarray Analysis of Gene Expression Profiles in Human Fibroblast Cells Irradiated with Red Light  Shipeng Song  Journal of Investigative Dermatology 
D.J. Askenazi, D.I. Feig, N.M. Graham, S. Hui-Stickle, S.L. Goldstein 
Differential effects of simvastatin on mesangial cells
Volume 67, Issue 4, Pages (April 2005)
Volume 56, Issue 5, Pages (November 1999)
Presentation transcript:

Volume 66, Issue 1, Pages 281-287 (July 2004) Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension  Daniel I. Feig, Takahiko Nakagawa, S. Ananth Karumanchi, William J. Oliver, Duk-Hee Kang, Jennifer Finch, Richard J. Johnson  Kidney International  Volume 66, Issue 1, Pages 281-287 (July 2004) DOI: 10.1111/j.1523-1755.2004.00729.x Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 1 Allopurinol lowers uric acid and blood pressure in adolescents with essential hypertension. Children were recruited from the Hypertension program at Texas Children's Hospital. The 5 children had confirmation of their hypertension by in-clinic, home, and ABP monitoring, and were diagnosed with essential hypertension as previously described. Inclusion criteria were newly diagnosed essential hypertension, no current or previous antihypertensive medications or diuretics, serum uric acid >6.0mg/dL, and normal renal function (Schwartz calculation >90cc/min/1.73m2). Subjects were treated with allopurinol at 200 mg bid for 4 weeks followed by a 6-week washout period off medications. No other interventions, such as exercise or dietary modifications, were made. Casual and ABPM measurements were performed immediately before treatment, at the end of 4 weeks of treatment while still on allopurinol, and 6 weeks after discontinuing the allopurinol. Serum uric acid was measured at the 3 BP measurement visits, as well as one week after the initiation of allopurinol to confirm a >40% decrease in serum uric acid levels. Numbers in parentheses are P values, calculated by paired t test, in comparison to pretreatment data. The study was open label, and compliance was assessed uric acid levels. No adverse events occurred during the trial. The study was approved by the Baylor Institutional Review Board. Kidney International 2004 66, 281-287DOI: (10.1111/j.1523-1755.2004.00729.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 2 Serum uric acid in adolescents with essential hypertension correlates inversely with the birth weight of the individual. In a retrospective chart review, the charts of patients enrolled in the Hypertension Program at Texas Children's Hospital were screened for birth weight. Ninety-five children were identified who had recorded birth weight, serum uric acid, and confirmed diagnosis of hypertension (diagnostic protocol described previously). The mean, standard error, and standard deviation of patient's birth weights as a function of their diagnosis are shown (A). The correlation analysis for birth weight and serum uric acid at the time of diagnosis of hypertension is shown (B). Kidney International 2004 66, 281-287DOI: (10.1111/j.1523-1755.2004.00729.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 3 Inhibition of glomerular endothelial cells by uric acid. Rat glomerular endothelial cells (passage 15, gift of Dr. Stephen Adler, Valhalla, NY) were growth arrested for 24 hours by serum starvation [in Dulbecco's modified Eagle's medium (DMEM) with 0.5% fetal bovine serum (FBS)] on 6-well plates. Cells were then incubated in DMEM (0.5% FBS) with or without uric acid (5 mg/dL) for 24 hours. 3H-thymidine (1 μCi/mL) was added to the culture plates 6 hours before harvest to quantify the glomerular endothelial cell proliferation. Thymidine uptake was assayed by liquid scintillation counting. Studies were performed in triplicate and the cells were all incubated at uniform conditions of 37°C, with 5% CO2. Comparison was by ANOVA with Bonferroni correction. Physiologic levels of uric acid can significantly inhibit the proliferation of glomerular endothelial cells, a step required for nephronogenesis during late pregnancy, consistent with the possibility that maternal elevations in serum uric acid could contribute to reduced nephron number in the fetus. Kidney International 2004 66, 281-287DOI: (10.1111/j.1523-1755.2004.00729.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 4 Hypothetical mechanism by which hyperuricemia leads to reduced nephron number and hypertension. Elevated maternal serum uric acid levels (or other inhibitors of endothelial cell proliferation) cross the placenta into the developing fetus during nephron development. Increases in fetal uric acid levels during the third trimester inhibit endothelial proliferation, a necessary step of nephron development, and reduce the final nephron number at birth. The lower congenital nephron number may lead to hyperuricemia during adolescence as a consequence of increased proximal reabsorption, and hyperuricemia may also result from genetic and environmental factors linked to maternal hyperuricemia. The hyperuricemia causes endothelial dysfunction and hyper-reninemia, which induces a salt-resistant hypertension. The combination of hyperuricemia with the hemodynamic consequences of low nephron number leads to subtle renal injury (arteriolopathy and interstitial inflammation) and the development of a renal-dependent, salt-sensitive hypertension that eventually becomes independent of serum uric acid levels. Kidney International 2004 66, 281-287DOI: (10.1111/j.1523-1755.2004.00729.x) Copyright © 2004 International Society of Nephrology Terms and Conditions